BYDUREON PACKAGE INSERT PDF DOWNLOAD

Learn about BYDUREON® BCiseTM including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information. Find dosing and administration information for BYDUREON Pen, including BYDUREON Pen packaging contains 4 pens .. BYDUREON [package insert]. PACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen.

Author: Daisida Najas
Country: Singapore
Language: English (Spanish)
Genre: Travel
Published (Last): 3 November 2014
Pages: 189
PDF File Size: 8.28 Mb
ePub File Size: 16.58 Mb
ISBN: 354-7-77473-227-9
Downloads: 34143
Price: Free* [*Free Regsitration Required]
Uploader: Dutaxe

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct bdyureon metformin for treatment of type 2 diabetes DURATION Acute Kidney Injury and Impairment of Renal Function Altered renal function, bydureon package insert increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation have been reported.

You may report side effects related to AstraZeneca products by clicking here. Hypersensitivity Reports of serious hypersensitivity reactions eg, anaphylaxis and bydureon package insert.

Injection-Site Reactions Serious reactions inzert, abscess, cellulitis, and necrosiswith or without subcutaneous nodules, have been reported. Not studied in patients with a history of pancreatitis. Macrovascular Outcomes No clinical studies establishing conclusive evidence of macrovascular risk reduction with bydureon package insert. J Clin Endocrinol Metab. J Clin Endocrinol Metab.

Efficacy and tolerability of the bydureon package insert byduroen suspension of exenatide once weekly inzert exenatide twice daily in patients with type 2 diabetes [published online ahead of print July 7, ].

You may report side effects related to AstraZeneca products by clicking here. Injection-Site Reactions Serious reactions eg, abscess, cellulitis, and necrosiswith or without subcutaneous nodules, have been reported.

By using this website you consent to our use of these cookies. Bydureon package insert are now leaving the AstraZeneca Australia website You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

BYDUREON Dosing and Administration

bydureon package insert Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes [published online ahead of print July 7, ].

Related Posts  ZAMBIAN LABOUR LAWS EBOOK DOWNLOAD

GLP-1 RA, glucagon-like peptide-1 receptor agonist. Encapsulation of exenatide in poly- D,L-lactideco-glycolide microspheres produced an investigational long-acting once-weekly formulation bydureon package insert type 2 diabetes. In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids dehydration which may cause kidney problems to get worse.

Patients with higher titer antibodies may have an attenuated HbA1c response. Bydureon package insert initiation, observe patients carefully for symptoms of pancreatitis. You may feel the pain from your abdomen to your back. Macrovascular Outcomes Bydureon package insert clinical studies establishing conclusive evidence of macrovascular risk reduction with exenatide. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes DURATION Consider other antidiabetic therapies in patients with a history of pancreatitis.

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – executive summary.

Encapsulation of exenatide in poly- D,L-lactide-co-glycolide microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Not a substitute for insulin. Consider other antidiabetic therapies in patients with a bydureon package insert of pancreatitis Hypoglycemia Risk of hypoglycemia is increased when exenatide is coadministered with insulin or insulin secretagogues.

Not recommended in patients with severe renal impairment or end-stage renal disease.

IMPORTANT SAFETY INFORMATION

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Use caution in patients with renal transplantation or moderate renal impairment. Use caution in patients with renal transplantation or moderate renal impairment. Hypoglycemia Risk of hypoglycemia is increased when exenatide bydureon package insert coadministered with insulin or insulin secretagogues. If suspected, discontinue bydureon package insert and do not restart if confirmed.

Some of these injection-site reactions have required surgery. Patients with higher titer antibodies may have an attenuated HbA1c response. Efficacy bydureon package insert isnert of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes DURATION Stomach problems Tell your healthcare provider if you have severe problems with your stomach, such as slowed emptying of your stomach gastroparesis bydureon package insert problems digesting food.

Related Posts  INTERVENCION EN CRISIS SLAIKEU EBOOK

Once-weekly dosing with BYDUREON® Pen (exenatide extended-release) injectable suspension | For HCPs

Use caution in patients with renal transplantation or moderate renal impairment Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal bydureon package insert reactions, not recommended in patients with severe gastrointestinal disease eg, gastroparesis Immunogenicity Patients may develop antibodies to exenatide. We encourage you to read the privacy policy of every website you visit. Kidney problems kidney failure Tell your healthcare provider if you have or had kidney problems.

Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. Acute Kidney Injury and Impairment of Renal Bydureon package insert Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation have been reported.

Bydureon package insert worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.

I disagree Bydureon package insert agree. Bydureon package insert statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – executive summary.

These may be symptoms of thyroid cancer. Consider other antidiabetic therapies in patients with a history of pancreatitis. Warfarin Increased international normalized ratio INR sometimes associated pacmage bleeding has been reported with concomitant use of exenatide with warfarin. Accessed October 18,